Use of BCG immunogenic formulation expressing a respiratory syncitial virus protein against hMPV
AssigneePontificia Universidad Catolica De Chile
InventorsAlexis Kalergis, Susan Bueno, Pablo González
Life of this patent
Estimating the term…
Abstract
The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 10-10° bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human Orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human Metapneumovirus (hMPV) infections.
Claims9
A method of protecting an individual against human Metapneumovirus (hMPV) infections, the method comprising administering to the individual an immunogenic formulation consisting of a strain of recombinant Bacillus Calmette-Guerin (BCG) at a concentration in a range from 104 to 109 colony forming units (CFU) per dose in a pharmaceutically acceptable saline buffer solution, wherein the recombinant BCG expresses the N protein of respiratory syncytial virus (RSV) or an immunogenic fragment thereof.
A method of inducing a humoral response specific to human Metapneumovirus (hMPV) in an animal comprising administering to the animal an immunogenic formulation consisting of a strain of recombinant Bacillus Calmette-Guerin (BCG) at a concentration in a range from 104 to 109 colony forming units (CFU) per dose in a pharmaceutically acceptable saline buffer solution, wherein the recombinant BCG expresses the N protein of RSV or an immunogenic fragment thereof.
Dependencies are inferred from the claim text.